Treatment of leg ulcers in β‐thalassaemia intermedia: use of platelet‐derived wound healing factors from the patient's own platelets

Gilsanz, Florinda; Escalante, Fernando; Auray, Claude; Olbés, Alicia G.

doi:10.1046/j.1365-2141.2001.03138.x

Cited by 15 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three applications of a combination of platelet extract and cryoprecipitate was also effective in treating chronic foot ulcer in a diabetic patient [86]. Similarly platelet extracts could treat an ankle ulcer of more than 4 years in a thalassemia patient [87]. These data are consistent with the fact that recombinant PDGF used in a topical gel has efficacy in the treatment of refractory chronic ulcers [45,[88][89].…”

Section: Wound Healingsupporting

confidence: 77%

Blood-Derived, Tissue Engineering Biomaterials

Burnouf¹

2004

Biomed. Eng. Appl. Basis Commun.

View full text Add to dashboard Cite

show abstract

Section: Wound Healingsupporting

confidence: 77%

Blood-Derived, Tissue Engineering Biomaterials

Burnouf¹

2004

Biomed. Eng. Appl. Basis Commun.

View full text Add to dashboard Cite

show abstract

“…Also, considering a limited reference list such that reported here, the articles claiming for the effectiveness of platelet gel are the great majority [1–5,9–18,21,22,25–29,35–56]. Some criticism is needed also in this case.…”

Section: Are There Clinical Evidences To Say That Platelet Gel Reallymentioning

confidence: 99%

Platelet‐rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point?

Borzini

Mazzucco

2007

ISBT Science Series

View full text Add to dashboard Cite

Background PubMed accessed on January 23 revealed 160 items about ‘platelet gel or releasate’ associated to topical therapy. Yahoo! provided 8580 items; Altavista 8650; Google 25 300. Companies providing blood separators are going to offer devices to prepare platelet‐rich plasma (PRP) for topical therapy. Several devices are filling the marketplace aiming to produce platelet gels for human therapy. Never‐ending lists of clinical conditions supposed to benefit from platelet gel application are published. Clinical benefits include bactericidal activity, pain reduction, tissue repair and regeneration. Are platelet derivatives the magic bullet for topical therapy? Methods Many in vitro studies account for clinical benefit from platelet gel. Several in vivo studies provide clinical evidence about healing of tissue repair induced by platelet derivatives. Nevertheless, systematic reviews reveal inadequate studies providing enough methodological strength to confirm evidence‐based efficacy. At present we must deal the subject with care using mostly inductive criteria. Only reproducible scientific data are to be considered. Every effort should be made for commercial, private and personal popularity‐related scenarios to be rejected from our consideration. Sometimes, this is not so simple to be done. Results There is a list of more than 60 biologically active platelet‐derived factors directly involved in tissue repair mechanisms: chemotaxis, cell proliferation, angiogenesis, extracellular matrix deposition and remodelling. Biological functions are also indirectly mediated by platelet‐derived growth factors; such functions are triggered by chemokines and cytokines produced by bystander cells such as fibroblasts, macrophages, endothelial cells, lymphocytes, under platelet‐derived factor stimulation. All of this is well demonstrated. Clinical studies endorsed with stringent randomized controlled trials are lacking. However, several serious studies have been published reporting clinical efficacy of platelet derivatives in many clinical areas. Considering these papers seriously, we maintain that in most cases, clinical efficacy is by far more than just a suggestion. Discussion Although we consider evidence‐based medicine (EBM) highly meaningful, we emphasize that medicine moved forwards also before EBM was conceived. We do not consider platelet gel and releasate such as a ‘magic bullet’, but we are strongly impressed by the results our group, and other groups have obtained treating a variety of tissue lesions in a variety of clinical conditions. Clinical benefits are a composite result of the lesion state, severity and duration, coexisting pathologies, patient's age and product characteristics. From our point of view, the last is a pivotal variable that has strong influence over the clinical outcome. Platelet‐rich plasma, platelet gel and platelet releasate need stringent definitions. Too many methods are used to prepare these products. Both methods and product need definition, validation, specific quality parameters and clin...

show abstract

“…Several terms are related to (PC) derivatives: PRP, plasma rich in growth factors, platelet‐enriched plasma, platelet gel, concentrated platelet‐rich plasma, platelet‐rich concentrates, platelet‐rich fibrin (PRF), concentrated growth factors, advanced PRF, titanium‐prepared PRF, injectable PRF, platelet‐derived wound healing factors, platelet‐derived biomaterials, platelet‐rich blood derivatives, platelet lysate, and platelet‐released growth factors. These PCs have their own characteristics and methods of preparation, standing time, transfer process, temperature of centrifugation, vibration, and clinical applications …”

Section: Discussionmentioning

confidence: 99%

Application of standardized platelet‐rich plasma in elderly patients with complex wounds

Tian

Cheng

Chen

et al. 2019

Wound Repair Regeneration

View full text Add to dashboard Cite

In recent years, autologous platelet-rich plasma (PRP) derivatives have been used widely in the regeneration and repair of tissue, but a standard definition and preparation method for PRP are lacking. We developed a standardized method using platelet indices as quality-control indicators for PRP preparation. Twenty-one elderly patients (9 males, 12 females) with complex wounds were treated with standardized platelet-rich plasma (S-PRP). The platelet count in PRP after the second centrifugation was 1,069-1,436 × 10 9 /L. We adjusted the platelet concentration in PRP after a second centrifugation to 1,000 × 10 9 /L according to a formula using platelet-poor plasma (PPP). The standardized preparation method that we developed gave S-PRP with a relatively uniform platelet concentration. The wounds of 21 patients showed accelerated healing after S-PRP treatment, and there were no obvious side effects during treatment. These data suggest that our preparation method of S-PRP, using platelet indices as quality-control indicators with platelet count of 1,000 × 10 9 /L could be used for the treatment of complex wounds in the elderly. The preparation method of S-PRP proposed in the present study may be a simple and effective method of PRP quality control.

show abstract

Treatment of leg ulcers in β‐thalassaemia intermedia: use of platelet‐derived wound healing factors from the patient's own platelets

Cited by 15 publications

References 2 publications

Blood-Derived, Tissue Engineering Biomaterials

Blood-Derived, Tissue Engineering Biomaterials

Platelet‐rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point?

Application of standardized platelet‐rich plasma in elderly patients with complex wounds

Contact Info

Product

Resources

About